Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) will release its fourth quarter and year-end 2020 financial results on March 8, after U.S. market close. A conference call will follow at 4:30 p.m. ET for a discussion of the results and a business update. Investors can access the live audio webcast via the company's website. The company is known for its innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat.

Positive

• Upcoming financial results announcement on March 8, 2021.
• Management will provide a business update during the conference call.

Negative

• None.

WALTHAM, Mass., March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 financial results on Monday, March 8, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, March 8, to discuss the Company's financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Conference ID: 7949816
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/wdaqmgg3

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

View original content:http://www.prnewswire.com/news-releases/syndax-to-announce-fourth-quarter-and-year-end-2020-financial-results-and-host-conference-call-and-webcast-on-march-8-2021-301236837.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals announce its Q4 and year-end 2020 financial results?

Syndax Pharmaceuticals will announce its financial results on March 8, 2021.

What time is the Syndax Pharmaceuticals conference call on March 8, 2021?

The conference call will take place at 4:30 p.m. ET on March 8, 2021.

How can I access the live webcast for Syndax Pharmaceuticals' earnings call?

The live webcast can be accessed through Syndax's Investors section of their website.

What are the key products in Syndax Pharmaceuticals' pipeline?

Syndax's pipeline includes SNDX-5613, axatilimab, and entinostat.